[Efficacy of sumamigren at early and late stages of migraine attack].
Three migraine attacks have been studied in 30 patients aged 39.4+/-10.5 years. A significant decrease of headache and concomitant symptoms was found 1, 2 and 6 h after receiving of sumamigren (sumatriptan). The drug was effective in 2 out of 3 attacks in most of the patients (53.3%); in 3 attacks--in 26.7%; in 1 attack--in 6.7%. In 13.3% of the patients the drug did not exert a therapeutic effect. When administering at the early stage of the attack, the drug reduced the headache after 1 and 2 h more significantly comparing to patients receiving it at the later stage. In case of early prescription of sumamigren, the relapse of headache was observed in 7,8% and in later one--in 20.5% of patients. During the first 24 h of attack, patients switched to the drug at the early stage reported higher quality of life (mean score 45.1+/-14.6) than those with later prescription (71.4+/-18.3). It has been concluded that sumamigren is an effective medication for stopping the migraine attack, in particular at its the beginning.
Tabeeva
G R
GR
Azimova
Iu E
IuE
D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy*; D010147:Pain Measurement; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D018170:Sumatriptan / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan